Yet another Class I ACCF/AHA for AstraZeneca's Brilinta
This article was originally published in Scrip
The American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) have updated their guidelines to include a Class I recommendation for AstraZeneca's Brilinta (ticagrelor) in patients with ST-elevation myocardial infarction (STEMI).
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.